Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
Not a traditional drug phase: None, this is a non-interventional observational study for Alzheimer's Disease(AD)
The goal of this international watch-and-measure (no experimental treatment required) study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers. The InRAD Registry watch-and-measure (no experimental treatment required) Study has several aims: * To collect medical information for many years from a large group of people with Alzheimer's disease.
Official registry: https://clinicaltrials.gov/study/NCT07213700 · Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · enrollment listed as 50,000
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 50,000 people at 23 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
Interventions: None, this is a non-interventional observational study
Primary outcome (registry wording): Transitions in Alzheimer's Disease Clinical Stage Over Time
Who it is for (from inclusion criteria)
Ages 18 Years to any
Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR
Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),
Be attending an InRAD Center,
Who the registry excludes
The protocol does not specify a lower or upper age limit. Participants are expected to be predominantly adults, and can include younger adults with early-onset or genetically determined Alzheimer's disease (e.g. Down syndrome-associated Alzheimer's disease)
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07213700?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07213700?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.